Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.
Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
Patients with cancer who develop venous thromboembolism (VTE) could reduce their risk of VTE recurrence with the direct oral anticoagulant (DOAC) apixaban, which demonstrated noninferiority to subcutaneous dalteparin in the Caravaggio* trial.
Rivaroxaban reduced venous thromboembolism (VTE) risk without increasing bleeding compared with enoxaparin in patients who underwent lower limb nonmajor orthopaedic surgery, the PRONOMOS* trial showed.
Dr. Dominick Angiolillo, Dr. George Dangas, 20200417100911
The TWILIGHT trial demonstrated that switching to ticagrelor
monotherapy after 3 months of dual antiplatelet therapy (DAPT) with ticagrelor
and aspirin significantly lowered the incidence of bleeding compared with
staying on DAPT, without increasing the risk of ischaemic events. Data from two
substudies, TWILIGHT-DM and TWILIGHT-Complex, presented at the American College
of Cardiology and World Congress of Cardiology 2020 virtual meeting (ACC/WCC
2020), showed consistent findings in patients with diabetes mellitus (DM) and
patients who underwent complex percutaneous coronary intervention (PCI).
Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis who are at low surgical risk appears to be safe with low rates of death or disabling stroke at 30 days, according to a study presented at the ACC.20/WCC Virtual Meeting.
A gout drug that’s been around for years reduced the risk of ischaemic cardiovascular (CV) events when given at a low dose in patients who had myocardial infarction (MI) and was cost-effective, an analysis of the COLCOT* trial has shown.
For patients undergoing CABG*, using a radial artery graft to create the second bypass conduit led to better 10-year survival and cardiovascular outcomes than using a saphenous vein grafting, according to the RADIAL** meta-analysis presented at the recent ACC.20/WCC Virtual Meeting.
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.